LBPMedicine(SH:688393)2025-02-25 08:25Financial Performance - Total revenue for 2024 was CNY 470.79 million, a decrease of 5.33% compared to the previous year[3] - Net profit attributable to shareholders was CNY 22.04 million, down 44.99% year-on-year[5] - Net profit excluding non-recurring items was CNY 13.70 million, a decline of 61.20% compared to the previous year[5] - Basic earnings per share decreased by 44.19% to CNY 0.24[3] Assets and Equity - Total assets at the end of the reporting period were CNY 1.36 billion, a decrease of 2.54% from the beginning of the period[5] - Shareholders' equity attributable to the parent company was CNY 1.26 billion, down 0.56% from the beginning of the period[5] Reasons for Decline - The decline in revenue and profit was primarily due to the implementation of centralized procurement policies affecting HPV products, leading to a gross profit reduction of approximately CNY 22 million[6] - Increased salaries for sales, marketing, and co-construction personnel contributed to the profit decline[6] Future Outlook - The company is expanding its professional talent team to accelerate market conversion of previous R&D results[5] Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be disclosed in the audited annual report[8]